文献速递腹部技术与安全CTMR

西方队列中连环蛋白β1突变型肝细胞癌的CT与MRI特征

CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort.
PubMed 文献 · Abdom Radiol (NY) · 2025-06-10

这项回顾性、经IRB批准的多读者单中心研究纳入160个初治、病理证实的肝细胞癌,评估CT与MRI影像特征与CTNNB1突变的关系;58个(36%)存在CTNNB1突变,突变型更常表现为孤立病灶、马赛克外观、病灶内血产物、坏死及病灶内动脉,但多重检验校正后无影像特征与突变状态显著相关。

要点

  • CTNNB1突变型肝细胞癌更常为孤立病灶(CT 60% vs 40%),并伴马赛克外观(MRI 26% vs 4.4%)。
  • CTNNB1突变型更常见病灶内血产物(CT 16% vs 2.5%;MRI 35% vs 12%)与坏死(CT 37% vs 18%)。
  • 多重检验校正后,无任何影像特征独立预测CTNNB1突变状态。

核心结论

  • 与野生型相比,CTNNB1突变型肝细胞癌更可能表现为含血产物、坏死和病灶内动脉的马赛克不均匀孤立肿块。
  • 在高危患者亚组中,多数CTNNB1突变肿瘤被归为LI-RADS LR-5。
  • 多重检验校正后,无影像特征独立预测CTNNB1突变型肝细胞癌。

研究设计与样本

  • 回顾性、经IRB批准的多读者单中心研究,纳入160个初治、病理证实的肝细胞癌。
  • 纳入患者接受增强CT、MRI或两者,并接受靶向肿瘤测序;中位年龄69岁(IQR 62, 75),男性125例。
  • 术前CT和MRI按LI-RADS特征及预后影像特征进行审阅。
  • 采用Fisher精确检验和多重检验校正评估影像特征与CTNNB1突变状态的关联。

关键影像表现/征象

  • CT上孤立病灶见于CTNNB1突变型26/43(60%) vs 野生型31/80(40%),p=0.024。
  • MRI上马赛克外观见于突变型9/34(26%) vs 野生型3/68(4.4%),p=0.002。
  • CT上病灶内血产物见于突变型7/43(16%) vs 野生型2/80(2.5%),p=0.009;MRI上为12/34(35%) vs 8/68(12%),p=0.008。
  • CT上坏死见于突变型16/43(37%) vs 野生型14/80(18%),p=0.026。
  • CT上病灶内动脉见于突变型26/43(60%) vs 野生型32/80(40%),p=0.038。

诊断标准与关键数值

  • 采用LI-RADS对98例高危患者(乙型肝炎、形态学肝硬化)进行归类,多数被归为LR-5(CT:突变型15/25[60%] vs 野生型21/52[40%];MRI:突变型10/18[56%] vs 野生型19/44[43%])。
  • 多重检验校正后,无影像特征与CTNNB1突变状态显著相关。

临床应用与阅片要点

  • 阅片时可关注孤立肿块、马赛克不均匀外观、病灶内血产物、坏死及病灶内动脉等征象,这些征象在CTNNB1突变型中更常见。
  • 高危患者中CTNNB1突变型肿瘤多数归为LR-5,但无影像特征可独立预测突变状态。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Various mutations in hepatocellular carcinoma (HCC) carry prognostic implications. The objective of this study is to assess CT and MRI imaging features associated with Catenin Beta-1 (CTNNB1) mutation in HCC.

METHODS: This retrospective, IRB- approved multi-reader, single-center study included treatment-naive, pathologic-proven HCC that underwent contrast-enhanced CT, MRI or both, with subsequent targeted tumor sequencing test. Preoperative CT and MRI were reviewed for the Liver Imaging Reporting and Data System (LI-RADS, LR) features and prognostic imaging features. Fisher's exact test and multiple testing adjustment were used to assess the association of imaging features and CTNNB1 mutation status.

RESULTS: Of the 160 HCCs included (median age 69 [IQR: 62, 75], 125 men), 58 (36%) had CTNNB1 mutation. Compared to wildtype, CTNNB1-mutated HCCs were more likely to be present as solitary lesion (CT: 26/43[60%] vs. 31/80 [40%], p = 0.024), have mosaic appearance (MRI: 9/34[26%] vs. 3/68[4.4%], p = 0.002), blood products in mass (CT: 7/43[16%] vs. 2/80[2.5%], p = 0.009; MRI: 12/34[35%] vs. 8/68[12%], p = 0.008), necrosis (CT: 16/43[37%] vs. 14/80[18]%, p = 0.026), intralesional arteries (CT: 26/43[60%] vs. 32/80[40%], p = 0.038). A subgroup of 98 high risk patients (hepatitis B, morphologic cirrhosis) were assigned LI-RADS categorization; majority of patients were assigned LR-5 (CT: 15/25[60%] vs. 21/52[40%]; MRI: 10/18[56%] vs. 19/44[43%]). No feature was significantly associated with CTNNB1 mutation status after multiple testing adjustment.

CONCLUSION: Compared to wildtype, CTNNB1-mutated HCCs are more likely to appear as solitary masses with mosaic, heterogeneous appearance containing blood products, necrosis and intralesional arteries. Majority of CTNNB1-mutated tumors were categorized as LR-5 in a subgroup of high risk patients. No imaging feature independently predicted CTNNB1-mutated HCCs.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Law W, Zheng J, Kim TH, et al. CT and MRI features of Catenin Beta 1-mutated hepatocellular carcinoma in a Western cohort. Abdom Radiol (NY). 2025. PMID: 40493177. doi:10.1007/s00261-025-05044-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。